Novo Nordisk SWOT Analysis
The Danish diabetes and obesity company that lost the injectable race to Eli Lilly and leads the pill race instead. Novo raised its 2026 guidance three times, from a -5% to -13% decline in adjusted sales and operating profit at constant exchange rates (February 3) to -4% to -12% (May 6), 0% to -6% (August 4) and -2% to +2% (November 4). Q3 2026 adjusted sales were DKK 79.2B, up 4% at CER against a DKK 73.6B FactSet consensus, and adjusted operating profit rose 27%. The Wegovy pill, launched in the US on January 5, 2026, sold DKK 2.3B, 3.2B and 5.4B in the first three quarters, has more than 8 million cumulative US prescriptions, and on Lilly's own count takes about 6 in 10 US oral obesity starts against Foundayo. The injectables are shrinking: Ozempic -5% and Wegovy injection -2% in Q3, semaglutide generics in Canada and India, and a $675 US list price from January 1, 2027. This SWOT centers on the 'Two-Market Split': Lilly leads injectables (Mounjaro plus Zepbound $16.07B in Q3, about 63% of the US incretin market), Novo leads pills (6.8% of its Q3 sales vs 0.75% of Lilly's, our calculation), which is why both raised guidance in the same quarter. CagriSema's FDA decision is expected around the turn of 2026-27, and the shares are about 74% below their June 2024 peak.
- 1Top strength — The Leading GLP-1 Pill: The Wegovy pill sold DKK 2.3 billion in Q1 2026, DKK 3.2 billion in Q2 and DKK 5.4 billion in Q3…
- 2Top weakness — The Injectables Are Shrinking: Ozempic fell 5% to DKK 29.7 billion and Wegovy injection 2% to DKK 20.4 billion in Q3…
- 3Biggest opportunity — CagriSema in 2027: Novo filed CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) with the FDA in December 2025; the…
Novo Nordisk SWOT Snapshot
| Category | Top factors |
|---|---|
| Strengths |
|
| Weaknesses |
|
| Opportunities |
|
| Threats |
|
The SWOT
every quadrant, every point ↘Novo Nordisk Strengths (2026)
6Novo Nordisk Weaknesses (2026)
6Novo Nordisk Opportunities (2026)
6Novo Nordisk Threats (2026)
6TOWS Strategy Matrix
PREMIUMFrom insight to action — pairing the four quadrants into concrete strategies.
Show 3 more ↓
Show 3 more ↓
Show 3 more ↓
Show 3 more ↓
Want to customize this analysis?
Tailor this Novo Nordisk SWOT to your specific context — your market, your goals, your strategy.
Beyond SWOT: other frameworks to try
SWOT is one of 100+ thinking frameworks on FrameworkList — covering strategy, prioritization, risk, business models, and decision-making.
Frequently Asked Questions
What are the Strengths of Novo Nordisk in their SWOT analysis?
+
- The Leading GLP-1 Pill: The Wegovy pill sold DKK 2.3 billion in Q1 2026, DKK 3.2 billion in Q2 and DKK 5.4 billion in Q3 (US DKK 4.2 billion), with more than 8 million cumulative US prescriptions since its January 5, 2026 launch, about 3.6 million of them in Q3.
- First to the Prescriber: Launched three months before Lilly's Foundayo (approved April 1, 2026), the Wegovy pill takes about 6 in 10 US oral obesity starts on Lilly's own Q3 count, and sold roughly $0.8 billion in Q3 against Foundayo's $184 million (at about 6.5 kroner per dollar, our calculation).
- Guidance Raised Three Times: The 2026 guide for adjusted sales and operating profit at constant exchange rates moved from -5% to -13% (February) to -2% to +2% (November), and Q3 adjusted sales of DKK 79.2 billion beat the DKK 73.6 billion FactSet consensus by more than DKK 5 billion.
- A Cost Reset That Shows in Profit: Q3 2026 adjusted operating profit rose 27% at CER to DKK 31.7 billion on 4% sales growth; the 2025 transformation cut full-time staff 10% to 68,794, and the free-cash-flow guide was raised to DKK 60-70 billion from DKK 45-55 billion.
- International Operations Still Growing: International Operations grew 8% at CER through the first nine months of 2026, and Wegovy (injection and pill) grew 31% outside the US in Q3.
- Diabetes Scale: Diabetes was 67% of FY2025 sales (DKK 309.1 billion, +10% CER) and obesity 26.6% (our calculation), and Novo held a 42.7% volume share of the global insulin market and 30.1% of the diabetes care market by value at November 2025.
What are the Weaknesses of Novo Nordisk in their SWOT analysis?
+
- The Injectables Are Shrinking: Ozempic fell 5% to DKK 29.7 billion and Wegovy injection 2% to DKK 20.4 billion in Q3 2026, and US Wegovy injection sales fell 15% over nine months on lower realized prices.
- The Pill Is Still Small: The Wegovy pill was 6.8% of Q3 2026 sales (our calculation), so its growth has to outrun a DKK 50.1 billion quarterly injectable business that is declining.
- The Head-to-Head Loss: In REDEFINE 4, CagriSema produced a 23% body-weight reduction against 25.5% for Lilly's tirzepatide over 84 weeks, and Copenhagen shares fell 16.5% on February 23, 2026; Novo's next injectable cannot be sold as the efficacy leader.
- Pipeline Write-Downs: Novo impaired DKK 4.0 billion for monlunabant in Q2 2026 and DKK 4.6 billion for ziltivekimab in Q3, plus DKK 4.1 billion to shrink its manufacturing network, so reported Q3 operating profit fell 9% while adjusted profit rose 27%.
- A Stock That Has Not Recovered: Shares fell from DKK 1,028 on June 25, 2024 to DKK 269 on November 6, 2026, about 74% (our calculation); the August guide raise closed 4.3% lower and the September 21 Capital Markets Day 7.7% lower.
- Finance Leadership Change: CFO Karsten Munk Knudsen leaves at the end of 2026 and will be succeeded by Luigi La Corte, currently CFO of Galderma, just as the January 2027 US list-price cut takes effect.
What are the Opportunities of Novo Nordisk in their SWOT analysis?
+
- CagriSema in 2027: Novo filed CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) with the FDA in December 2025; the decision is expected around the turn of 2026-27 and Novo is preparing a US launch in early 2027, subject to approval.
- Medicare Coverage: A Medicare GLP-1 Bridge pilot has covered obesity treatment since July 1, 2026, a reimbursed population that both the pill and the injectables can serve.
- Branded Telehealth Distribution: Since a March 9, 2026 agreement that ended Novo's lawsuit, Hims & Hers sells branded Wegovy at cash prices and stops marketing compounded copies, with a carve-out for 'clinically necessary' compounding.
- More Pill Markets and Formats: The Wegovy pill is sold in 8 markets at US self-pay prices of $149 to $299 a month by dose, ships without a cold chain, and the Ozempic pill followed in the US on May 4, 2026.
- MASH Through Akero: Novo closed the Akero acquisition on December 9, 2025 for $54 a share in cash (about $4.7 billion) plus a $6 contingent value right tied to efruxifermin's approval in MASH cirrhosis, a liver-disease asset outside GLP-1.
- A Rebuilt Pipeline Target: The September 21, 2026 Capital Markets Day set a goal of more than five multi-blockbusters by 2030, giving investors a public scorecard for the post-semaglutide pipeline.
What are the Threats of Novo Nordisk in their SWOT analysis?
+
- Semaglutide Generics Abroad: The compound patent expired in India, China and Brazil in March 2026 and the Canadian patent lapsed over unpaid maintenance fees; generics have launched in India and Canada, and Novo's Q3 report cites the Canadian loss of exclusivity as a drag on Ozempic. US, European and Japanese exclusivity runs into the early 2030s.
- The January 2027 List-Price Cut: Under the November 2025 agreement with the US administration, the US list price of Wegovy and Ozempic falls to $675 a month on January 1, 2027, about 50% and 35% below current list; Q1 2027 is the first quarter at that price.
- Lilly in Injectables: Lilly holds about 63% of the US incretin market, grew Mounjaro 65% and Zepbound 49% in Q3 2026, and plans a retatrutide filing in Q1 2027.
- Foundayo's Broader Rollout: Lilly's pill has launched in the UAE, UK, Saudi Arabia and Mexico and is under review in more than 40 more countries, so Novo's roughly 6-in-10 share of US oral starts will be tested as Foundayo scales.
- Amgen and Later Entrants: Amgen's MariTide reports Phase 3 data (MARITIME-1 and -2) in 2027 after about 20% weight loss at 52 weeks in Phase 2, a 2027-28 threat rather than a 2026 one.
- Coverage Pullbacks: Novo's Q3 2026 report cites reduced Medicaid obesity coverage as a headwind, on top of lower US realized prices for Wegovy injection.
More Examples
Nestlé SWOT analysis 2026: 9M sales CHF 65.87B (+3.7% organic growth), Q3 RIG accelerating to +2.8% while pricing cools to +1.1%, H1 FCF up 46.3% to CHF 3.38B but net profit down 31.4%. Centers on the 'Four-Pillar Volume Test' as CEO Philipp Navratil cuts 16,000 jobs, narrows media spend to 150 brands, and exits Waters (Peranel JV) and mainstream VMS ($1.0B).
Read analysis →Honda SWOT analysis 2026: a first operating loss of ¥414.3bn after EV write-offs, record motorcycle profit, a pivot to hybrids and an FY27 guide raised to ¥780bn on Nov 10. Strengths, weaknesses, opportunities & threats.
Read analysis →Pinterest SWOT analysis 2026: 661 million users, a Q3 revenue miss, Europe ARPU down 7%, a weak Q4 guide and the EU de minimis hit. Strengths, weaknesses, opportunities & threats.
Read analysis →Analyze any company in 30 seconds
Free to start · No credit card · Your SWOT in under a minute.
Analyze Free →